CA3063322A1 - Enhanced solubility drug-containing formulations - Google Patents

Enhanced solubility drug-containing formulations Download PDF

Info

Publication number
CA3063322A1
CA3063322A1 CA3063322A CA3063322A CA3063322A1 CA 3063322 A1 CA3063322 A1 CA 3063322A1 CA 3063322 A CA3063322 A CA 3063322A CA 3063322 A CA3063322 A CA 3063322A CA 3063322 A1 CA3063322 A1 CA 3063322A1
Authority
CA
Canada
Prior art keywords
composition
acid
acids
combination
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3063322A
Other languages
English (en)
French (fr)
Inventor
Michael Laird Hurrey
Drazen Ostovic
Peter NOYMER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Steadymed Ltd
Original Assignee
Steadymed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steadymed Ltd filed Critical Steadymed Ltd
Publication of CA3063322A1 publication Critical patent/CA3063322A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3063322A 2017-05-11 2018-05-10 Enhanced solubility drug-containing formulations Pending CA3063322A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762504546P 2017-05-11 2017-05-11
US62/504,546 2017-05-11
PCT/IL2018/050511 WO2018207188A1 (en) 2017-05-11 2018-05-10 Enhanced solubility drug-containing formulations

Publications (1)

Publication Number Publication Date
CA3063322A1 true CA3063322A1 (en) 2018-11-15

Family

ID=62599659

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3063322A Pending CA3063322A1 (en) 2017-05-11 2018-05-10 Enhanced solubility drug-containing formulations

Country Status (9)

Country Link
US (1) US11672863B2 (https=)
EP (1) EP3621591A1 (https=)
JP (1) JP2020519593A (https=)
KR (1) KR20200018438A (https=)
CN (1) CN110869000A (https=)
AU (1) AU2018265624A1 (https=)
CA (1) CA3063322A1 (https=)
IL (1) IL271673A (https=)
WO (1) WO2018207188A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3621591A1 (en) 2017-05-11 2020-03-18 Steadymed Ltd. Enhanced solubility drug-containing formulations
AU2020323594B2 (en) * 2019-08-01 2022-02-03 Incarda Therapeutics, Inc. Antiarrhythmic formulation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3910260A (en) 1972-03-01 1975-10-07 Survival Technology Method and apparatus of treating heart attack patients prior to the establishment of qualified direct contact personal care
US4004577A (en) 1972-12-04 1977-01-25 Survival Technology, Inc. Method of treating heart attack patients prior to the establishment of qualified direct contact personal care
US3941130A (en) 1975-03-18 1976-03-02 Tibbs Robert C Sequential trigger release for injection device
US4261358A (en) 1979-10-01 1981-04-14 Walter Vargas Automatic syringe plunger
US4795433A (en) 1985-05-20 1989-01-03 Survival Technology, Inc. Automatic injector for emergency treatment
US4689042A (en) 1985-05-20 1987-08-25 Survival Technology, Inc. Automatic medicament ingredient mixing and injecting apparatus
US4902692A (en) * 1988-03-18 1990-02-20 Iolab Corporation Method and composition for ophthalmic anesthesia using rodocaine
US5085642A (en) 1989-07-17 1992-02-04 Survival Technology, Inc. Conveniently carried frequent use autoinjector
US5102393A (en) 1989-07-17 1992-04-07 Survival Technology, Inc. Autoinjector converted from intramuscular to subcutaneous mode of injection
US5092843A (en) 1990-04-12 1992-03-03 Survival Technology, Inc. Dispersion multichamber auto-injector
US5267963A (en) 1992-08-21 1993-12-07 Nicholas Bachynsky Medication injection device
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
DK0659073T3 (da) * 1992-09-10 2002-03-11 Childrens Medical Center Bionedbrydelige polymermatrixer med vedvarerende afgivelse af lokalanæstetika
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5747060A (en) * 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
CA2304096C (en) * 1997-09-18 2003-09-09 Pacira Pharmaceuticals, Inc. Sustained-release liposomal anesthetic compositions
US6149626A (en) 1997-10-03 2000-11-21 Bachynsky; Nicholas Automatic injecting syringe apparatus
SE9803662D0 (sv) 1998-10-26 1998-10-26 Pharmacia & Upjohn Ab Autoinjector
JP4775807B2 (ja) * 2004-12-02 2011-09-21 株式会社 メドレックス 局所麻酔薬物含有ゼリー剤
US20060270708A1 (en) * 2005-05-25 2006-11-30 Navinta Llc Novel process for preparation of isotonic aqueous injection of ropivacaine
MX2008016335A (es) 2006-06-30 2009-01-21 Abbott Biotech Ltd Dispositivo automatico de inyeccion.
CN101744760A (zh) * 2008-12-18 2010-06-23 梁颖 用于难溶性或易分解性药物的缓释体
CN102106806B (zh) * 2009-12-29 2013-04-17 上海中西制药有限公司 一种固体制剂的制备方法及所得固体制剂
CA2910865C (en) * 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
EP3375456B1 (en) * 2015-11-12 2023-05-03 Terumo Kabushiki Kaisha Sustained-release topically administered agent
EP3621591A1 (en) 2017-05-11 2020-03-18 Steadymed Ltd. Enhanced solubility drug-containing formulations

Also Published As

Publication number Publication date
KR20200018438A (ko) 2020-02-19
US11672863B2 (en) 2023-06-13
JP2020519593A (ja) 2020-07-02
CN110869000A (zh) 2020-03-06
US20200054754A1 (en) 2020-02-20
WO2018207188A1 (en) 2018-11-15
IL271673A (en) 2020-02-27
EP3621591A1 (en) 2020-03-18
AU2018265624A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
AU2018264078B2 (en) Novel analgesic compositions
JP6574228B2 (ja) 局所麻酔薬のデポー製剤及びその調製方法
EP1809329B1 (en) Sustained local anesthetic composition containing saib
CN115804771A (zh) 一种具有长效缓释作用的脂质释药系统及其制备方法
TW202237108A (zh) 供注射用羅哌卡因長效溶液製劑及其製備方法
US11672863B2 (en) Enhanced solubility drug-containing formulations
McKinley Pharmacological Implications of Drug Administration Routes
WO2007022609A1 (en) Pharmaceutical composition of morphine in ready-to-use injectable solution form and single dosage form of morphine for epidural or intrathecal administration
EP2874602B1 (en) Injectable supersaturated acetaminophen solution for spinal administration
CN119656101A (zh) 一种长效缓释溶致液晶凝胶制剂及制备方法
WO2022175973A1 (en) An injectable composition for long term delivery of nalbuphine or nalbuphine ester prodrug or its salts and use thereof
TWI472340B (zh) Taxanes containing solution and a preparation method of the co-solvent
US20230270755A1 (en) Combination of medications in a parenteral dosage form for long-term anaesthesia
TR2021009613T (tr) Bi̇r yeni̇ uzun süreli̇ anestezi̇ sağlayan i̇laç kombi̇nasyonu
WO2011047636A1 (zh) 一种含有助溶剂的紫杉烷类药物溶液及其制备方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230510

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240731

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20241112

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20241202

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20251112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251230